
Comorbidities and Disability Progression in MS

Vascular comorbidity in MS is associated with increased risk of disability progression,¹ ambulatory disability, visual disability, brain atrophy, and worsening health-related quality of life²

Vascular comorbidities include current diagnosis of hypertension, hyperlipidemia, diabetes, obesity, cardiovascular disease, peripheral vascular disease, or tobacco use (definitions vary)

Smoking is associated with:

- Increased risk of developing MS³
- Increased risk of disease activity, progression, and brain atrophy³
- Increased risk of death⁴
- Depression and anxiety⁵



- 1. Marrie RA et al. Neurology. 2010;74:1041-1047; 2. Shangraw K et al. Int J MS Care. 2022;24:169-174; 3. Rosso M, Chitnis T. JAMA Neurol. 2020;77:245-253;
- 4. Manouchehrinia A et al. J Neurol Neurosurg Psychiatry. 2014;85:1091-1095; 5. McKay KA et al. Mult Scler. 2016;22:685-693; 6. Binzer S et al. Neurology. 2019;93:e2216-e2223.

Impact of Smoking Cessation on Disability Progression in MS



Reference group: never-smokers	Hazard ratio (95% CI)	
	EDSS score 4.0	EDSS score 6.0
Former smokers	1.09 (0.81 to 1.46)	0.96 (0.69 to 1.32)
Current smokers	2.42 (1.63 to 3.60)	1.86 (1.19 to 2.91)
Each smoke-free years after cessation	0.96 (0.95 to 0.97)	0.97 (0.95 to 0.98)

10 smoke-free years can account for a 33% and 26% lower risk of reaching EDSS scores 4.0 and 6.0 in former smokers compared with current smokers

The earlier patients quit smoking, the stronger the reduction in risk of reaching disability milestones

Lifestyle Modification and Comorbidity Management: Patient Counseling

Modifiable factors that affect function and/or disease progression

Body weight/ body mass index

Diet

Exercise

Mental and social stimulation

Psychological stress

Sleep hygiene

Substance use (alcohol, tobacco, marijuana)

Vascular risk factors